Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

11,450.00ILa
27 Apr 2017
Change (% chg)

80.00 (+0.70%)
Prev Close
11,370.00
Open
11,330.00
Day's High
11,510.00
Day's Low
11,330.00
Volume
692,960
Avg. Vol
602,397
52-wk High
21,770.00
52-wk Low
11,160.00

Latest Key Developments (Source: Significant Developments)

Teva Pharmaceutical Industries expects that sales of authorized generic will represent most of sales of two products
Thursday, 20 Apr 2017 08:42am EDT 

April 20 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva launches airduo™ respiclick® and its authorized generic, two inhalers containing fluticasone propionate and salmeterol.Teva Pharmaceutical Industries Ltd- Expects that sales of authorized generic will represent most of sales of two products.  Full Article

Teva Pharmaceuticals received a warning letter from the U.S. FDA
Thursday, 13 Apr 2017 08:34am EDT 

Teva Pharmaceutical Industries Ltd :Teva Pharmaceutical Industries Ltd - on April 10, received a warning letter from the U.S. Food and Drug Administration (FDA) - SEC filing.  Full Article

Teva announces FDA approval of AUSTEDO tablets for treatment of chorea associated with huntington’s disease
Monday, 3 Apr 2017 05:04pm EDT 

Teva Pharmaceutical Industries Ltd - : Teva announces FDA approval of AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with huntington’s disease .AUSTEDO is expected to be available in U.S. within next 3 weeks..  Full Article

OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico
Monday, 20 Mar 2017 10:07am EDT 

OncBioMune Pharmaceuticals Inc : OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico . Term sheet sets forth guidelines for co to acquire sanitary registration, intellectual property rights of Norepinefrine .Norepinefrine is currently owned by Teva.  Full Article

Teva says FDA granted priority review for SD-809 for treatment of tardive dyskinesia
Tuesday, 28 Feb 2017 08:00am EST 

Teva Pharmaceutical Industries Ltd : Teva Pharmaceutical Industries Ltd - FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 30, 2017. .Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia.  Full Article

Teva sees 2017 adjusted profit $4.90 to $5.30/shr
Monday, 13 Feb 2017 06:42am EST 

Teva Pharmaceutical Industries Ltd : Teva reports full year and fourth quarter 2016 financial results . Sees fy 2017 non-gaap earnings per share $4.90 to $5.30 . Sees fy 2017 revenue $23.8 billion to $24.5 billion . Q4 revenue rose 33 percent to $6.5 billion . Teva pharmaceutical industries ltd - reaffirms its 2017 full year non-gaap guidance . Teva pharmaceutical industries ltd - teva reaffirms its 2017 full year non-gaap guidance . Teva pharmaceutical industries ltd - qtrly non-gaap eps $1.38 . Teva pharmaceutical industries ltd- generic medicines revenues in q4 of 2016 were $3.7 billion, an increase of 44% compared to q4 of 2015 . Teva pharmaceutical industries ltd - qtrly gaap loss per share $1.10 . Teva pharmaceutical industries ltd says specialty medicines revenues in q4 of 2016 were $2.2 billion, up 4% compared to q4 of 2015 .Teva pharmaceutical industries ltd - qtrly global revenues of copaxone in u.s. And globally, were $1.0 billion, an increase of 6% compared to q4 of 2015.  Full Article

Teva appoints Dr. Yitzhak Peterburg as interim CEO
Monday, 6 Feb 2017 04:53pm EST 

Teva Pharmaceutical Industries Ltd : Teva appoints Dr. Yitzhak Peterburg as interim chief executive officer, succeeding Erez Vigodman . Teva Pharmaceutical Industries Ltd - Sol J. Barer named chairman of board . Teva Pharmaceutical Industries Ltd - board of directors is undertaking a search to identify a permanent chief executive officer . Teva Pharmaceutical Industries Ltd- Yitzhak Peterburg has stepped down from his role as chairman in order to serve as interim chief executive officer .Teva Pharmaceutical Industries Ltd says Erez Vigodman is stepping down following a mutual agreement between board of Teva and Vigodman.  Full Article

Teva confirms generic Victoza patent challenge in the United States
Thursday, 2 Feb 2017 08:00am EST 

Teva Pharmaceutical Industries Ltd : Teva confirms generic Victoza patent challenge in the united states . Teva Pharmaceutical Industries Ltd - filed ANDA with FDA seeking approval to market generic version of Novo Nordisk's Victoza (liraglutide) injection .Teva Pharmaceutical Industries Ltd - should its ANDA be approved, Teva may be entitled to 180 days of generic market exclusivity.  Full Article

ISS Germany wins contract with Teva Pharmaceuticals
Wednesday, 1 Feb 2017 09:40am EST 

Iss A/S : ISS Germany wins contract with Teva Pharmaceuticals . ISS Germany's Pharma Services will serve as Teva GmbH's new facility services provider .Teva has signed a 5-year contract with ISS, effective Jan. 1.  Full Article

Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation
Tuesday, 31 Jan 2017 08:00am EST 

Momenta Pharmaceuticals Inc :Momenta Pharmaceuticals announces district court decision to invalidate Teva Pharmaceuticals patents in copaxone 40 mg/ml litigation.  Full Article

More From Around the Web

Photo

Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year.